Edition:
United States

SCYNEXIS Inc (SCYX.OQ)

SCYX.OQ on NASDAQ Stock Exchange Global Market

2.29USD
15 Dec 2017
Change (% chg)

$0.07 (+3.15%)
Prev Close
$2.22
Open
$2.23
Day's High
$2.32
Day's Low
$2.23
Volume
34,418
Avg. Vol
33,338
52-wk High
$3.81
52-wk Low
$1.53

Latest Key Developments (Source: Significant Developments)

Scynexis reports third quarter 2017 financial results
Tuesday, 7 Nov 2017 04:20pm EST 

Nov 7 (Reuters) - Scynexis Inc :Scynexis reports third quarter 2017 financial results and provides company update.Q3 loss per share $0.31.Q3 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S.  Full Article

Scynexis CEO Marco Taglietti​ buys 10,000 shares of co's common stock on Aug 15
Thursday, 17 Aug 2017 09:36am EDT 

Aug 17 (Reuters) - Scynexis Inc :Scynexis Inc CEO‍ Marco Taglietti​ reports purchase of 10,000 shares of co's common stock on Aug 15 at $1.61 per share - SEC filing.  Full Article

Scynexis Q2 loss per share $0.16
Tuesday, 8 Aug 2017 04:25pm EDT 

Aug 8 (Reuters) - Scynexis Inc :Scynexis reports second quarter 2017 financial results and provides company update.Q2 loss per share $0.16.Q2 earnings per share view $-0.31 -- Thomson Reuters I/B/E/S.  Full Article

Scynexis Q1 loss per share $0.19
Monday, 8 May 2017 04:20pm EDT 

May 8 (Reuters) - Scynexis Inc ::Scynexis reports first quarter 2017 financial results and provides update on iv formulation development status.Q1 loss per share $0.19.Q1 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S.  Full Article

Scynexis delays initiation of new clinical studies
Thursday, 2 Mar 2017 04:05pm EST 

Scynexis Inc : Scynexis delays initiation of new clinical studies using the IV formulation of SCY-078 at FDA's request . Scynexis Inc says ongoing and future trials using oral formulation of SCY-078 are unaffected by this regulatory action . Scynexis -meeting with FDA to discuss these data and to agree on subsequent clinical studies with iv formulation of SCY-078 is scheduled for Q2 of 2017 .Scynexis -FDA has informed company to hold initiation of any new clinical studies with intravenous (IV) formulation of SCY-078 until FDA completes review.  Full Article

Scynexis enters into loan and security agreement with Solar Capital
Wednesday, 5 Oct 2016 04:03pm EDT 

Scynexis Inc : On September 30, 2016, Co entered into loan and security agreement with Solar Capital Ltd. - SEC filing .Solar providing Co with 48-month secured term loan of $15 million and all principal and accrued interest on term loan due on Sept 30, 2020.  Full Article

Scynexis announces sale of Cyclophilin inhibitor assets to Cypralis Ltd
Wednesday, 13 Jul 2016 08:30am EDT 

Scynexis Inc : Scynexis announces sale of Cyclophilin inhibitor assets to Cypralis Ltd .Financial terms of agreement were not disclosed..  Full Article

Scynexis says CEO Marco Taglietti purchased 100,000 shares - SEC filing
Tuesday, 28 Jun 2016 10:00am EDT 

Scynexis Inc : CEO Marco Taglietti reports purchase of 100,000 shares of co's common stock on June 24 at $2.39 per share - SEC filing Source: (http://1.usa.gov/29bI1Ch ) Further company coverage: [SCYX.O] (Bengaluru Newsroom: +1 646 223 8780).  Full Article

Scynexis director Guy Macdonald reports purchase of 40,000 shares - SEC filing
Tuesday, 28 Jun 2016 09:59am EDT 

Scynexis Inc : Director Guy Macdonald reports purchase of 40,000 shares of co's common stock on June 24 at $2.39 per share - SEC filing Source: (http://1.usa.gov/290khhU ) Further company coverage: [SCYX.O] (Bengaluru Newsroom: +1 646 223 8780).  Full Article

Scynexis receives orphan drug designation for SCY-078
Friday, 13 May 2016 08:00am EDT 

Scynexis Inc : Scynexis Inc Receives orphan drug designation for SCY-078 for the treatment of invasive Candida infections .Expects top line data from two ongoing phase 2 studies of SCY-078's oral formulation in June and July 2016.  Full Article

BRIEF-Scynexis reports third quarter 2017 financial results

* Scynexis reports third quarter 2017 financial results and provides company update